Newsroom

RICHARDSON, Texas--(BUSINESS WIRE)--Healthcare data analytics leader MedeAnalytics and agentic AI innovator Basys.ai announced a strategic partnership that will benefit health payers....

PALO ALTO, Calif.--(BUSINESS WIRE)--Work AI leader Glean today announced it has doubled its annual recurring revenue (ARR) to $200 million, nine months after surpassing the $100 million milestone. The achievement places Glean among the fastest-growing pure-play enterprise software companies of the decade and underscores the accelerating demand for AI that drives real business outcomes. With this milestone, Glean has more than doubled its enterprise footprint and expanded across North America, E...

加州聖卡洛斯--(BUSINESS WIRE)--(美國商業資訊)-- 全球腫瘤治療創新公司BeOne Medicines Ltd.（Nasdaq: ONC; HKEX: 06160; SSE: 688235）在美國佛羅里達州奧蘭多舉行的第67屆美國血液學會（ASH）年會暨展覽會上展示公司血液學產品組合的深度、高品質和良好的發展趨勢，進一步證實了其在慢性淋巴細胞白血病（CLL）創新治療領域的領先地位。BeOne在ASH大會上展示的資料進一步證實了BRUKINSA ®（澤布替尼）可作為治療首選的基石性布魯頓氏酪胺酸激酶抑制劑（BTK抑制劑）。 BeOne副總裁暨血液學醫學長、醫學博士Amit Agarwal表示：「我們在2025年ASH大會上所展示的CLL產品組合新資料展現了BRUKINSA的實力和BGB-16673的潛力。長期數據是CLL治療的黃金標準，BRUKINSA持續展現出高水平的持久無進展生存期和總生存期特徵，符合患者和醫生對BTK抑製劑的期待。BGB-16673是目前臨床開發進展最快的BTK降解劑，已有800多例患者接受給藥。這款藥物有望引領腫瘤治療領域新一波創新。」 在超過...

PALO ALTO, Calif.--(BUSINESS WIRE)--On December 11, 2025, Rivian (NASDAQ: RIVN) will host AI and Autonomy Day at its Palo Alto Offices. The event will be livestreamed on the Rivian YouTube channel. About Rivian: Rivian (NASDAQ: RIVN) is an American automotive manufacturer that develops and builds category-defining electric vehicles as well as software and services that address the entire lifecycle of the vehicle. The company creates innovative and technologically advanced products that are desi...

WESTMONT, Ill.--(BUSINESS WIRE)--Gamma Technologies (GT), a global leader in multi-physics systems simulation software is proud to announce the launch of a new direct entity in Japan, Gamma Technologies G.K., a major step forward in strengthening our commitment to supporting innovation and transformation for our customers in the region. Complementing this strategic move, GT is also extending its long-standing strategic partnership with our exclusive distributor in Japan, IDAJ Co., Ltd., a premi...

BETHESDA, Md.--(BUSINESS WIRE)--Walker & Dunlop, Inc. announced today that it arranged a comprehensive financing package to facilitate the development of 22 Fulton Street, a premier, luxury multifamily project located within a Qualified Opportunity Zone in Newark, New Jersey. Walker & Dunlop Capital Markets Institutional Advisory, led by Aaron Appel, Keith Kurland, Jonathan Schwartz, Adam Schwartz, Jordan Casella, Michael Ianno, and Jackson Irwin, arranged the full financing package on...

NEW YORK & SINGAPORE--(BUSINESS WIRE)--Stonepeak, a leading alternative investment firm specializing in infrastructure and real assets, today announced the launch of Peregrine Cold Logistics (“Peregrine” or the “Platform”), a new cold chain logistics platform in Asia Pacific and the GCC, to meet the accelerating demand for temperature-controlled infrastructure across the region. Headquartered in Singapore, Peregrine will target cold chain opportunities across key markets including the ASEAN reg...

MALVERN, Pa.--(BUSINESS WIRE)--LifeScan (the “Company”), a world leader in blood glucose monitoring, today announced its successful emergence from its Chapter 11 financial restructuring process following approval of its Plan of Reorganization on October 27, 2025. Through this process, the Company eliminated more than 75% of its debt, providing the financial flexibility needed to continue its leadership in the glucose management industry. In connection with emergence, LifeScan is now owned by a...

DENVER--(BUSINESS WIRE)--Lumen Technologies, Inc. (“Lumen,” “us,” “we” or “our”) (NYSE: LUMN) today announced that its wholly-owned subsidiary, Level 3 Financing, Inc. (“Level 3 Financing”), has agreed to sell $1.25 billion aggregate principal amount of its 8.500% Senior Notes due 2036 (the “Notes”), which represents a $500 million increase from the previously announced size of the offering. The Notes were priced to investors at a price of 100.000% of their aggregate principal amount and will m...

SAN CARLOS, Calif.--(BUSINESS WIRE)--BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), een mondiaal oncologisch bedrijf, herbevestigt zijn positie als leider in innovaties voor chronische lymfatische leukemie (CLL) door de breedte, kwaliteit en het momentum van zijn hematologisch portfolio te demonstreren op de 67ste jaarlijkse vergadering en expositie van ASH in Orlando, Florida. Deze bekendmaking is officieel geldend in de originele brontaal. Vertalingen zijn slechts als leeshulp...